Homepage Featured

Manufacturing is now a biotech strategy problem, not a vendor problem.

CAR-T Platform Moves Novel Therapies from Gene Sequence to Clinic-ready in Under 12 Months

CAR-T has a geography problem

The Next Cancer Revolution Isn’t Scientific—It’s Manufacturing

Outsourced Pharma Capacity Update October 2025: Cell & Gene Therapy

Rethinking Lentiviral Manufacturing for Cell and Gene Therapies: from Platform Design to Point-of-care Delivery

Strategies for Efficiency and Affordability in Cell and Gene Therapy

Global Access to Cell and Gene Therapy: ARM Studios Interview with Boro Dropulić

Scroll to Top